Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates

TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-W...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Mayanka, Macaluso, Anthony, Myscofski, Dawn, Prigge, Jon, Koide, Fusataka, Noyce, Ryan S., Fogarty, Siobhan, Stillwell, Helen, Goebel, Scott J., Daugherty, Bruce, Nasar, Farooq, Bavari, Sina, Lederman, Seth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674175/
https://www.ncbi.nlm.nih.gov/pubmed/38006014
http://dx.doi.org/10.3390/vaccines11111682
_version_ 1785140766565203968
author Awasthi, Mayanka
Macaluso, Anthony
Myscofski, Dawn
Prigge, Jon
Koide, Fusataka
Noyce, Ryan S.
Fogarty, Siobhan
Stillwell, Helen
Goebel, Scott J.
Daugherty, Bruce
Nasar, Farooq
Bavari, Sina
Lederman, Seth
author_facet Awasthi, Mayanka
Macaluso, Anthony
Myscofski, Dawn
Prigge, Jon
Koide, Fusataka
Noyce, Ryan S.
Fogarty, Siobhan
Stillwell, Helen
Goebel, Scott J.
Daugherty, Bruce
Nasar, Farooq
Bavari, Sina
Lederman, Seth
author_sort Awasthi, Mayanka
collection PubMed
description TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.
format Online
Article
Text
id pubmed-10674175
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106741752023-11-02 Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates Awasthi, Mayanka Macaluso, Anthony Myscofski, Dawn Prigge, Jon Koide, Fusataka Noyce, Ryan S. Fogarty, Siobhan Stillwell, Helen Goebel, Scott J. Daugherty, Bruce Nasar, Farooq Bavari, Sina Lederman, Seth Vaccines (Basel) Article TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans. MDPI 2023-11-02 /pmc/articles/PMC10674175/ /pubmed/38006014 http://dx.doi.org/10.3390/vaccines11111682 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Awasthi, Mayanka
Macaluso, Anthony
Myscofski, Dawn
Prigge, Jon
Koide, Fusataka
Noyce, Ryan S.
Fogarty, Siobhan
Stillwell, Helen
Goebel, Scott J.
Daugherty, Bruce
Nasar, Farooq
Bavari, Sina
Lederman, Seth
Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
title Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
title_full Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
title_fullStr Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
title_full_unstemmed Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
title_short Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
title_sort immunogenicity and efficacy of tnx-1800, a live virus recombinant poxvirus vaccine candidate, against sars-cov-2 challenge in nonhuman primates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674175/
https://www.ncbi.nlm.nih.gov/pubmed/38006014
http://dx.doi.org/10.3390/vaccines11111682
work_keys_str_mv AT awasthimayanka immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT macalusoanthony immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT myscofskidawn immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT priggejon immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT koidefusataka immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT noyceryans immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT fogartysiobhan immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT stillwellhelen immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT goebelscottj immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT daughertybruce immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT nasarfarooq immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT bavarisina immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates
AT ledermanseth immunogenicityandefficacyoftnx1800alivevirusrecombinantpoxvirusvaccinecandidateagainstsarscov2challengeinnonhumanprimates

Ejemplares similares